BioCentury | Jun 11, 2020
Deals

Prism’s peptide mimetic platform finds second discovery partner

...using its peptide mimetic platform. Financial terms and therapeutic focus of Monday’s deal are undisclosed. Prism BioLab...
...initiation factor 4E binding protein 1 REST (NRSF) - RE1-silencing transcription factor Elizabeth S. Eaton, Staff Writer PRISM BioLab...
BioCentury | Apr 12, 2012
Distillery Therapeutics

Indication: Cancer

...Inc., is in Phase I/II testing to treat colorectal cancer. PRI-724, a CTNNB1 inhibitor from Prism BioLab Corp....
BioCentury | Aug 5, 2010
Distillery Therapeutics

Indication: Pulmonary disease

...cancer. SciBX 3(30); doi:10.1038/scibx.2010.928 Published online Aug. 5, 2010 ICG-001 and its uses patented by Prism BioLab...
Items per page:
1 - 3 of 3
BioCentury | Jun 11, 2020
Deals

Prism’s peptide mimetic platform finds second discovery partner

...using its peptide mimetic platform. Financial terms and therapeutic focus of Monday’s deal are undisclosed. Prism BioLab...
...initiation factor 4E binding protein 1 REST (NRSF) - RE1-silencing transcription factor Elizabeth S. Eaton, Staff Writer PRISM BioLab...
BioCentury | Apr 12, 2012
Distillery Therapeutics

Indication: Cancer

...Inc., is in Phase I/II testing to treat colorectal cancer. PRI-724, a CTNNB1 inhibitor from Prism BioLab Corp....
BioCentury | Aug 5, 2010
Distillery Therapeutics

Indication: Pulmonary disease

...cancer. SciBX 3(30); doi:10.1038/scibx.2010.928 Published online Aug. 5, 2010 ICG-001 and its uses patented by Prism BioLab...
Items per page:
1 - 3 of 3